Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TECX

Tectonic Therapeutic Inc

Feb 13 • 04:00PM ET

22.28

-0.43 -1.89 %

Healthcare • Biotechnology • USA • NASD

Feb 10, 4:30 AMAstraZeneca's discontinuation of relaxin mimetic AZD3427 trial due to efficacy concerns sparked premarket plunge.

Peers: VRTX REGN AMGN GILD BIIB BMRN INCY EXEL NBIX RGEN

| Held by: VTI IWM VXF IBB IWN VTWO IWC SBIO IWO BBC

Index	RUT	P/E	-	EPS (ttm)	-3.85	Insider Own	43.25%	Shs Outstand	18.71M	Perf Week	-8.58%
Market Cap	417.00M	Forward P/E	-	EPS next Y	-4.83	Insider Trans	0.11%	Shs Float	10.61M	Perf Month	13.27%
Enterprise Value	149.22M	PEG	-	EPS next Q	-1.11	Inst Own	63.85%	Short Float	35.52%	Perf Quarter	18.13%
Income	-67.30M	P/S	-	EPS this Y	38.74%	Inst Trans	2.64%	Short Ratio	9.83	Perf Half Y	-8.95%
Sales	0.00M	P/B	1.56	EPS next Y	-15.50%	ROA	-30.20%	Short Interest	3.77M	Perf YTD	6.81%
Book/sh	14.30	P/C	1.55	EPS next 5Y	6.98%	ROE	-32.21%	52W High	36.11 -38.30%	Perf Year	-35.27%
Cash/sh	14.37	P/FCF	-	EPS past 3/5Y	41.06% 26.54%	ROIC	-25.15%	52W Low	13.70 62.63%	Perf 3Y	11.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.39% 10.47%	Perf 5Y	-88.49%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	60.41%	Oper. Margin	-	ATR (14)	2.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	29.15	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.66	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	29.15	EPS Q/Q	15.44%	SMA20	4.88%	Beta	1.58	Target Price	79.38
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	8.21%	Rel Volume	1.07	Prev Close	22.71
Employees	51	LT Debt/Eq	0.00	Earnings	Nov 06 AMC	SMA200	10.37%	Avg Volume	383.58K	Price	22.28
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.39% -	Trades		Volume	411,173	Change	-1.89%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$101
Sep-03-25	Initiated	Oppenheimer	Outperform	$80
Jul-21-25	Initiated	Truist	Buy	$64
Jun-11-25	Resumed	Raymond James	Outperform	$76
Apr-21-25	Initiated	Mizuho	Outperform	$51
Nov-20-24	Initiated	Raymond James	Outperform	$65
Aug-22-24	Initiated	Wells Fargo	Overweight	$55
Jun-26-24	Initiated	Piper Sandler	Overweight
Jun-24-24	Initiated	TD Cowen	Buy
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$24 → $7
Jun-15-21	Initiated	BTIG Research	Buy	$23
May-27-21	Initiated	Needham	Buy	$28
Mar-09-21	Initiated	Barclays	Overweight	$23
Mar-02-21	Initiated	Stifel	Hold	$14
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral	$13
Jun-27-19	Initiated	Mizuho	Buy	$28
Apr-05-19	Initiated	Janney	Buy

Show Previous Ratings

Feb-11-26 04:01PM	Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 (GlobeNewswire)
Dec-10-25 02:13PM	Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating (Insider Monkey)
Dec-01-25 08:00AM	Tectonic Therapeutic to Participate in December Investor Conferences (GlobeNewswire)
Nov-06-25 04:01PM	Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +15.51%
Oct-29-25 04:01PM	Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF (GlobeNewswire) -5.48%
09:00AM	Loading…
Aug-28-25 09:00AM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-07-25 04:01PM	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -5.35%
Jun-30-25 08:00AM	Tectonic Therapeutic Joins Russell 3000 Index (GlobeNewswire)
Jun-24-25 05:42PM	Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating (Insider Monkey) +7.57%
May-17-25 10:40AM	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 (GlobeNewswire)
May-13-25 09:55AM	Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? (Zacks)
May-08-25 04:01PM	Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +10.81% -5.99%
May-07-25 08:00AM	Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference (GlobeNewswire)
May-01-25 05:59AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks Earning Wall Streets Seal of Approval (TipRanks) -5.75%
Apr-23-25 05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
08:00AM	Loading…
Apr-15-25 08:00AM	Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 (GlobeNewswire)
Mar-20-25 04:01PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:26PM	Is Tectonic Therapeutic, Inc. (TECX) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-20-25 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-03-25 06:30AM	Tectonic Announces $185 Million Private Placement (GlobeNewswire) -6.52%
Jan-30-25 06:30AM	Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF (GlobeNewswire) +113.22%
Dec-03-24 04:01PM	Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 (GlobeNewswire)
Nov-26-24 04:01PM	Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-12-24 11:01PM	Tectonic Therapeutic Inc. Reports Q3 2024 Results (TipRanks)
Nov-11-24 05:00AM	Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein (GlobeNewswire)
Nov-07-24 04:01PM	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-24 04:01PM	Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 (GlobeNewswire)
Sep-19-24 04:01PM	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 (GlobeNewswire)
Aug-20-24 04:01PM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 04:01PM	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +5.23%
04:01PM	Loading…
Jul-30-24 04:01PM	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 (GlobeNewswire)
Jun-20-24 04:01PM	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million (Business Wire)
09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace)
08:26AM	Why Is Avrobio (AVRO) Stock Moving Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)
Apr-06-22 12:36PM	bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn (Zacks)
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-22 12:54PM	Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study (Zacks)
07:00AM	AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-17-22 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update (Business Wire) +8.33%
Mar-01-22 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences in March (Business Wire)
Feb-21-22 12:14PM	2 Net Current Asset Value Stocks to Consider (GuruFocus.com)
Feb-09-22 12:55PM	After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data (Benzinga) -6.25%
07:00AM	AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis (Business Wire)
Feb-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-22 10:00AM	Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks (Zacks)
Feb-01-22 07:00AM	AVROBIO Announces the Appointment of Sean OBryan as Chief Regulatory Officer (Business Wire)

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
REICIN ALISE	Chief Executive Officer	Feb 11 '26	Buy	21.10	2,500	52,750	237,547	Feb 12 04:15 PM
Schwabish Marc	Chief Business Officer	Feb 10 '26	Option Exercise	2.38	4,500	10,710	25,814	Feb 12 04:15 PM
Lochner Daniel	Chief Financial Officer	Feb 10 '26	Buy	21.61	6,000	129,660	32,044	Feb 11 05:32 PM
REICIN ALISE	Chief Executive Officer	Dec 31 '25	Option Exercise	2.38	10,966	26,099	239,151	Jan 05 05:02 PM
McNamara Peter	Chief Scientific Officer	Dec 22 '25	Option Exercise	2.98	7,000	20,860	40,879	Dec 29 04:35 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	53,706	875,945	1,503,358	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	45,858	767,204	1,449,652	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	21,071	311,020	1,403,794	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	16.31	9,478	154,586	4,334,846	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	16.73	8,092	135,379	4,325,368	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	14.76	3,718	54,880	4,317,276	Apr 11 06:12 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	412,500	7,053,750	1,382,723	Apr 09 05:38 PM
SPRINGER TIMOTHY A	Director	Apr 07 '25	Buy	17.10	87,500	1,496,250	4,313,558	Apr 09 05:38 PM
MCGUIRE TERRANCE	Director	Apr 07 '25	Sale	17.10	500,000	8,550,000	573,062	Apr 07 05:02 PM

Open in Screener

RNAC

Cartesian Therapeutics Inc

Feb 13 • 04:00PM ET

6.52

+0.11 1.72 %

Healthcare • Biotechnology • USA • NASD

RNAC Cartesian Therapeutics Inc daily Stock Chart

Peers: ALNY IONS SRPT ARWR PBYI BLUE CRSP EDIT GILD VRTX

| Held by: VTI IWM VXF IWN VTWO IWC IWO VTWV RSSL VTWG

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	65.76%	Shs Outstand	26.00M	Perf Week	0.46%
Market Cap	169.54M	Forward P/E	-	EPS next Y	-3.42	Insider Trans	-0.05%	Shs Float	8.90M	Perf Month	-14.66%
Enterprise Value	38.76M	PEG	-	EPS next Q	-0.85	Inst Own	21.33%	Short Float	24.28%	Perf Quarter	-13.98%
Income	-	P/S	-	EPS this Y	47.68%	Inst Trans	-2.03%	Short Ratio	13.14	Perf Half Y	-42.96%
Sales	-	P/B	-	EPS next Y	-45.55%	ROA	-	Short Interest	2.16M	Perf YTD	-9.57%
Book/sh	-1.38	P/C	1.18	EPS next 5Y	5.88%	ROE	-	52W High	20.00 -67.40%	Perf Year	-65.74%
Cash/sh	5.51	P/FCF	-	EPS past 3/5Y	12.72% 34.24%	ROIC	-	52W Low	5.98 9.03%	Perf 3Y	-88.50%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-22.95% 42.27%	Gross Margin	-	Volatility	4.76% 5.95%	Perf 5Y	-95.27%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-645.78%	Oper. Margin	-	ATR (14)	0.44	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.00	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	10.67	EPS Q/Q	-355.12%	SMA20	-6.35%	Beta	0.44	Target Price	35.57
Payout	-	Debt/Eq	-	Sales Q/Q	-98.65%	SMA50	-9.52%	Rel Volume	0.41	Prev Close	6.41
Employees	66	LT Debt/Eq	-	Earnings	Nov 06 BMO	SMA200	-30.78%	Avg Volume	164.50K	Price	6.52
IPO	Jun 22, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	-62.91% 69.73%	Trades		Volume	68,007	Change	1.72%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-25	Initiated	Wedbush	Outperform	$38
Dec-19-24	Initiated	BTIG Research	Buy	$42
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform	$50
May-24-24	Initiated	Mizuho	Buy	$40
Apr-23-24	Reiterated	H.C. Wainwright	Buy	$2 → $54
Apr-23-24	Initiated	Leerink Partners	Outperform	$39
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform	$1
Jun-14-22	Reiterated	Needham	Buy	$6 → $5
Jun-06-22	Initiated	SVB Leerink	Outperform	$7
Jun-15-21	Initiated	BTIG Research	Buy	$10
Jan-26-21	Upgrade	Mizuho	Neutral → Buy	$2.50 → $8
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Oct-01-20	Downgrade	Mizuho	Buy → Neutral	$2.50
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy	$8
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight	$10
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy	$33

Show Previous Ratings

Feb-03-26 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jan-14-26 12:00PM	Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-09-26 08:04AM	Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook (GlobeNewswire)
Jan-06-26 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Dec-18-25 04:05PM	Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors (GlobeNewswire)
04:05PM	Loading…
Nov-13-25 04:05PM	Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis (GlobeNewswire)
Nov-06-25 07:00AM	Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
07:00AM	Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company's Board of Directors (GlobeNewswire)
Oct-28-25 08:45AM	Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates (Zacks) -5.99%
Oct-21-25 03:53AM	Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength? (Zacks)
Oct-03-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
Aug-28-25 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 07:00AM	Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -6.56%
Aug-05-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -5.21%
07:40AM	Loading…
Jul-24-25 07:40AM	Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jun-24-25 02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks) +5.39%
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
04:41AM	Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength? (Zacks)
Jun-03-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
May-30-25 07:00AM	Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
May-13-25 07:00AM	Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-08-25 07:00AM	Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 05:35PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -15.03%
May-05-25 07:48AM	Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
May-02-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Apr-08-25 07:00AM	Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial (GlobeNewswire) -5.84%
Apr-02-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
07:00AM	Loading…
Apr-01-25 07:00AM	Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.24%
Mar-14-25 12:15PM	Amgen data muddies outlook for Cartesian, says Oppenheimer (TipRanks)
Mar-13-25 07:00AM	Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
Feb-18-25 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-06-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jan-27-25 07:00AM	Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis (GlobeNewswire)
Jan-13-25 07:00AM	Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases (GlobeNewswire) +8.85%
Jan-07-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Dec-20-24 06:50AM	Cartesian Therapeutics initiated with a Buy at BTIG (TipRanks)
Dec-18-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -7.59%
Dec-04-24 06:33AM	Cartesian Therapeutics Reports Promising Phase 2b Trial Results (TipRanks) +9.56%
Dec-03-24 06:00AM	Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial (GlobeNewswire)
Nov-21-24 07:00AM	Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit (GlobeNewswire)
Nov-14-24 10:01AM	Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 (GuruFocus.com)
Nov-08-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Nov-07-24 07:00AM	Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 09:00AM	Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting (GlobeNewswire)
Oct-15-24 07:00AM	Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting (GlobeNewswire) -5.58%
Oct-04-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +7.45%
Sep-09-24 07:00AM	Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis (GlobeNewswire)
Sep-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -7.55%
Sep-03-24 07:00AM	Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 (GlobeNewswire) -6.02%
Aug-26-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.43%
Aug-07-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-08-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-03-24 02:25PM	Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates (Zacks) +11.73%
Jul-02-24 04:08PM	Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs (Investor's Business Daily) -35.02%
04:05PM	Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing (GlobeNewswire)
06:30AM	Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Jun-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
May-23-24 12:12PM	Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08 (Zacks)
May-22-24 07:00AM	Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis (GlobeNewswire)
May-13-24 04:30PM	Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire) +15.38%
12:00PM	What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet (Zacks)
May-10-24 03:12PM	Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ... (GuruFocus.com)
May-08-24 02:52PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 04:15PM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire) -9.85%
Apr-25-24 09:55AM	Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade (Zacks)
Apr-22-24 04:30PM	Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting (Business Wire) +12.76%
Apr-08-24 09:35AM	Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC) (Zacks)
Apr-04-24 07:30AM	Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
07:00AM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey) -5.36% -7.55%
Mar-28-24 04:05PM	Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split (GlobeNewswire) -13.83%
Mar-14-24 09:35AM	Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-07-24 11:51PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -8.04%
07:00AM	Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-05-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
07:00AM	Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland (GlobeNewswire)
Feb-05-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -9.18% +5.35%
Jan-22-24 09:19AM	Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today? (InvestorPlace)
Jan-08-24 07:10AM	Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity (GlobeNewswire) +5.87%
07:00AM	Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Nov-13-23 08:05AM	Selecta Biosciences Announces Merger with Cartesian Therapeutics (GlobeNewswire) -8.00%
Oct-31-23 04:03PM	Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi (GlobeNewswire) -7.20%
Aug-24-23 06:21AM	The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collab (American City Business Journals)
Aug-17-23 10:20PM	Q2 2023 Selecta Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics (GlobeNewswire)
Jul-14-23 07:08AM	Selecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26% (Simply Wall St.)
Jul-13-23 03:00PM	10 Best Revenue Growth Stocks to Buy (Insider Monkey)
Jun-03-23 08:20AM	Selecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five years (Simply Wall St.)
May-31-23 07:00AM	Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology (GlobeNewswire)

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHRISTOPHER M JEWELL	Former Affiliate	Jan 13 '26	Proposed Sale	7.66	9,000	68,940		Jan 13 04:04 PM
CHRISTOPHER M JEWELL	Former Affiliate	Jan 09 '26	Proposed Sale	8.02	1,510	12,105		Jan 09 04:35 PM
Brunn Carsten	President and CEO	Jan 06 '26	Sale	6.82	23,766	162,077	323,530	Jan 08 04:20 PM
Miljkovic Milos	Chief Medical Officer	Jan 06 '26	Sale	6.82	3,573	24,367	58,820	Jan 08 04:19 PM
Davis Blaine	Chief Financial Officer	Jan 06 '26	Sale	6.82	10,591	72,227	121,220	Jan 08 04:19 PM
English Emily	Chief Operations Officer	Dec 30 '25	Option Exercise	3.30	7,500	24,750	70,226	Jan 02 04:03 PM
BARABE TIMOTHY C	Director	Dec 04 '25	Buy	6.86	30,000	205,797	54,366	Dec 08 04:07 PM
English Emily	Chief Operations Officer	Nov 28 '25	Option Exercise	3.30	7,500	24,750	62,726	Dec 02 04:02 PM
CHRISTOPHER M JEWELL	Former Affiliate	Nov 19 '25	Proposed Sale	7.15	26,935	192,585		Nov 19 04:36 PM
English Emily	Chief Operations Officer	May 12 '25	Option Exercise	3.30	7,500	24,750	55,226	May 14 04:15 PM
English Emily	Chief Operations Officer	Apr 15 '25	Option Exercise	3.30	7,500	24,750	47,726	Apr 16 04:35 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	10.47	48,595	508,751	620,175	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	9.43	41,782	393,947	571,580	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	10.77	36,338	391,455	656,513	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	10.47	8,575	89,773	8,637,273	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	9.43	7,373	69,517	8,628,698	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	10.77	6,412	69,074	8,643,685	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Mar 20 '25	Buy	15.59	54,889	855,593	8,621,325	Mar 20 07:50 PM
SPRINGER TIMOTHY A	Director	Mar 19 '25	Buy	14.97	20,234	302,962	8,566,436	Mar 20 07:50 PM
SPRINGER TIMOTHY A	Director	Mar 18 '25	Buy	14.42	14,740	212,599	8,546,202	Mar 20 07:50 PM

TECX

Tectonic Therapeutic Inc

RNAC

Cartesian Therapeutics Inc

Upgrade your FINVIZ experience